Research topics
Modulation and suppression of antitumour immunity, epigenetic regulations in tumour immunology, HPV16-associated tumours, immunotherapy of MHC class I-positive and -deficient tumours, gene and cell immunotherapy, minimal residual tumour disease.
Current grant support
Grant Agency of the Czech Republic (grants Nos.: 301/07/1410, 301/09/1024, 301/10/2174)
Academy of Sciences of the Czech Republic (grant No.:, IAA500520807)
Clinigene Network of Excellence for the Advancement of Gene Transfer and Therapy EU-FP6 Project No. 0189337)
The Internal Agency of Ministry od Health of the Czech republic (grant No.: NS10660-3)
Most important recent papers
(2004-present; names of the lab members underlined)Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, Bubenik J, Vonka V. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol 24(1): 161-7, 2004. (Pubmed)
Reinis M, Indrova M, Mendoza L, Mikyskova R, Bieblova J, Bubenik J, Simova J. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol 25(4): 1165-70, 2004. (Pubmed)
Mikyskova R, Bubenik J, Vonka V, Smahel M, Indrova M, Bieblova J, Simova J, Jandlova T. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int J Oncol 26(2): 521-7, 2005. (Pubmed)
Reinis M, Simova J, Bubenik J. Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours. Int J Cancer 118(7): 1836-42, 2006. (Pubmed) (DOI)
Indrova M, Bieblova J, Jandlova T, Vonka V, Pajtasz-Piasecka E, Reinis M. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 28(1): 253-9, 2006. (Pubmed)
Simova J, Bubenik J, Bieblova J, Rosalia RA, Fric J, Reinis M. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int J Oncol 29(6): 1567-71, 2006. (Pubmed)
Reinis M, Weiser B, Kuiken C, Dong T, Lang D, Nachman S, Zhang Y, Rowland-Jones S, Burger H. Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressors. AIDS Res Hum Retroviruses 23(2): 309-15, 2007. (Pubmed) (DOI)
Reinis M, Simova J, Indrova M, Bieblova J, Pribylova H, Moravcova S, Jandlova T, Bubenik J. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours. Int J Oncol 30(4): 1011-7, 2007. (Pubmed)
Reinis M, Simova J, Indrova M, Bieblova J, Bubenik J. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. Int J Oncol 30(5): 1247-51, 2007. (Pubmed)
Indrova M, Bieblova J, Bubenik J, Reinis M. IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 32(2): 499-507, 2008. (Pubmed)
Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J, Reinis M. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123(2): 218-27, 2008. (Pubmed) (DOI)
Indrova M, Bieblova J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubenik J, Reinis M. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol 34(1): 173-9, 2009. (Pubmed)
Kemal KS, Reinis M, Weiser B, Burger H. Methods for viral RNA isolation and PCR amplification for sequencing of near full-length HIV-1 genomes. Methods Mol Biol 485: 3-14, 2009. (Pubmed) (DOI)
Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, Bubenik J. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol 36(3): 545-51, 2010. (Pubmed)
Simova J, Indrova M, Bieblova J, Mikyskova R, Bubenik J, Reinis M. Therapy for minimal residual tumor disease: beta-Galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy. Int J Cancer. 2009 Sep 8. [Epub ahead of print] (Pubmed) (DOI)
Reviews
Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 25(2): 487-91, 2004. (Pubmed)
Reinis M. Technology evaluation: TroVax, Oxford BioMedica. Curr Opin Mol Ther 6(4): 436-42, 2004. (Pubmed)
Bubenik J, Simova J. Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review). Oncol Rep 14(5): 1377-80, 2005. (Pubmed)
Niederhafner P, Reinis M, Sebestik J, Jezek J. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J Pept Sci 14(5): 556-87, 2008. (Pubmed) (DOI)
Reinis M. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas. Curr Opin Mol Ther 10(5): 526-34, 2008. (Pubmed)
Bubenik J. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours. Curr Cancer Drug Targets 8(3): 180-6, 2008. (Pubmed)